Clinical Trials by Tumor Biology & Microbiology Program Members

Dr. Vaishampayan is conducting a pilot trial of oral cabozantinib/ XL184 in metastatic castrate resistant prostate cancer to explore the changes in bone and tumor imaging related pathways (KCI Protocol # 2011-185). It is now closed to accrual, but research related intervention and follow up are ongoing.

In collaboration with Dr. Gadgeel (MT), Dr. Hillman studies the effects of soy isoflavones on decreasing or preventing the inflammation associated with lung cancer radiation therapy (Hillman G, J Thorac Oncol, 2013). Based on this study, there is a PI-initiated clinical trial of Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients with Stage IIIA-IIIB Non-Small Cell Lung Cancer (KCI protocol #2013-021).

Drs. Vaishampayan and Heath (MT) are co-investigators on a multi-institutional study to evaluate immune responses to Sipuleucel-T in African American men and non-African American men with castrate resistant prostate cancer (Protocol #2013-108) which is a multi-center grant involving the Prostate Cancer Clinical Trials consortium [(Barbara Ann Karmanos Cancer Center (Wayne State University), Carbone Cancer Center (University of Wisconsin), Dana-Farber Cancer Institute (Harvard Medical School), Duke Cancer Institute, Fred Hutchinson Cancer Research Center (University of Washington), Helen Diller Family Comprehensive Cancer Center (University of California San Francisco), Knight Cancer Institute (Oregon Health and Science University), MD Anderson Cancer Center (University of Texas), Memorial Sloan Kettering Cancer Center, Sidney Kimmel Comprehensive Cancer Center (Johns Hopkins University), University of Chicago Comprehensive Cancer Center, University of Medicine and Dentistry of New Jersey, and Henry Ford Health System. 

More Information

For more information on these trials, or to view all clinical trials available at Karmanos Cancer Institute, please click here

The Latest From Karmanos Cancer Institute

News

U CAN-CER VIVE Gives $450K+ to Karmanos Cancer Institute for Continued Research in Using Radiofrequency to Treat Cancer

The Barbara Ann Karmanos Cancer Institute has been awarded $459,010 for continued research in treating cancers with radiofrequency electromagnetic...

Read More

New Grant Allows Karmanos Researchers to Continue Research Using Electromagnetic Radiofrequency Fields to Treat Fibrolamellar Carcinoma

A Barbara Ann Karmanos Cancer Institute and Wayne State University research team has received a $49,500 grant to research a rare cancer. The grant...

Read More

IN THE NEWS – New Hope for Myeloma Patients: Karmanos Advances Treatment and Survival

Telegram News Craig Cole, M.D. , malignant hematologist and member of the  Hematology Oncology  and  Multiple Myeloma and Amyloidos...

Read More
News

WDET | Doctor Says HPV Vaccine and Routine Screenings Aid Against Cervical Cancer

Listen Now

WWJ | World Cancer Day

Listen Now

WWJ | Ribbon Cutting Held for New Karmanos Cancer Center in Dearborn That Strives to Improve Access to Treatment, Clinical Trials

Listen Now